Why ImmunityBio Stock Is Soaring Today
Key Points
Immunotherapy Anktiva is now approved in 33 countries, with a slew of these approvals taking shape just this week.
In markets where it’s already been approved, the young treatment is experiencing strong growth.
Interested investors that can stomach the risk should at least consider the volatility that’s likely to linger after today’s sharp move.
Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason? Unsurprisingly, an approval of its breadwinning drug in another huge market.
Approved... again
ImmunityBio's oncology drug Anktiva had already been approved as a treatment for certain forms of bladder cancer as early as 2024, for the record, when the United States' FDA gave the immunotherapy the green light. The United Kingdom followed suit in the middle of 2025, with the Kingdom of Saudi Arabia coming around in January of this year.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
On Wednesday, however, the company announced that the European Union's regulatory commission has approved the combination of its Anktiva and vaccine Bacillus Calmette-Guérin (BCG) as treatment for non-muscle invasive bladder cancer in the 30 countries it represents.
The market's bullish response is understandable too, given what we know about demand for the immunotherapy thus far. Although the drug's only been sold within the U.S. for less than two years and only won the UK's approval a few months ago, the company expects to report $113 million worth of Anktiva revenue for the fiscal year ending in December, with quarter-over-quarter growth of 20% in the final quarter of 2025 alone. That's a lot for a relatively new drug in one market, and a nearly brand-new drug in another. It's still years away from reaching its peak sales potential.
Image source: Getty Images.
Bladder cancer isn't Anktiva's only target either. ImmunityBio is also testing the drug as a treatment for solid tumors, Lynch Syndrome, HIV, ovarian cancer, and Non-Hodgkin Lymphoma.
Just respect the risk
There's potential upside here to be sure. ImmunityBio is a relatively small company (a market cap of less than $8 billion) with a promising cancer therapy that should be competitive within a worldwide oncology market Global Market Insights expects to grow from less than $350 billion last year to more than $860 billion in 2034, with the cancer immunotherapy piece of this market alone expected to be worth $277 billion by 2032. That's roughly twice its current size. Even capturing just some of this growth could prove to be a windfall for ImmunityBio.
Still, interested investors must respect the fact that such extreme bullish volatility can invite near-term profit-taking. It wouldn't be wrong for anyone who can stomach the risk to let today's dust settle before jumping in.
Should you buy stock in ImmunityBio right now?
Before you buy stock in ImmunityBio, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and ImmunityBio wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $415,256!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,133,904!*
Now, it’s worth noting Stock Advisor’s total average return is 889% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 18, 2026.
James Brumley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Related Articles
Eurozone Inflation Gradually Recedes Will ECB Rate-Cut Window Open Again? 2026 Euro Exchange Rate Trend Forecast
TradingKey - After enduring three consecutive years of "high prices, high interest rates, high debt, and low growth," the Eurozone economy is finally demonstrating resilience through a moderate recovery. Currently, the European Central Bank (ECB) faces the ultimate test of maintaining the status quo versus implementing "preemptive rate cuts." Euro exchange rate volatility, inflation trends, and the economic outlook have become the primary focus for investors and financial enthusiasts when allocating overseas assets and capitalizing on currency opportunities.
AMD Stock Price Prediction 2030: Can AMD Narrow Nvidia’s AI Lead?
TradingKey - In the past couple of years, the semiconductor industry has experienced a major change. One question that investors still have is whether or not AMD (AMD) will be able to keep up with Nvidia (NVDA) as far as AI is concerned. What is the possible future of AMD's stock through 2026 and be
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?
